Teva Hits Low Signal Prescription

1. TEVA is a global player in the field of generic drugs, it is also one of the top 25 US Purple Chip stocks.

2. Market Capitalization of $USD 39 billion and a dividend of 1.8%. S&P rating is 3 stars, with a target of $USD 48.00.

3. Attractive ROC of 47% and an earnings yield of 5.7%. PE multiple at 8X earnings, a very low figure.

4. [sub]

5. LOW VALUATION IN TEVA AT $USD 42.00 (TEVA-US, $USD 42.90)

6. Assuming that earnings continue their trend, the Purple Chips model sees a reasonable valuation around $USD 52.00

7. 

   [/sub]